Investigational Drug for Genetic Form of ALS Improves Disease’s Molecular Signs
Investigational Drug for Genetic Form of ALS Improves Disease’s Molecular Signs An investigational drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) reduced molecular signs of the fatal, paralyzing disease and curbed neurodegeneration — but at the six-month mark, the drug did not improve motor control